# A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

> **NCT00528372** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1067 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00528372
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-02
- **Final completion:** 2010-07
- **Target enrollment:** 1067 (ACTUAL)
- **Last updated:** 2015-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528372, "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00528372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*